Psyence Biomedical Ltd. PBM
Psyence Biomedical Ltd. (Nasdaq: PBM) is a CNS/neurology/psychiatry drug developer. Its lead program, NPX-5 (nature-derived psilocybin 25 mg), is in Phase 2 for Adjustment disorder in patients with incurable cancer (palliative care). Its next catalyst on record is Ibogaine: TIRC and PsyLabs agreed to conclude definitive ibogaine supply agreement by November 30, 2026. (November 2026).
Upcoming catalysts
- November 2026Ibogaine — TIRC and PsyLabs agreed to conclude definitive ibogaine supply agreement by November 30, 2026.
PsyLabs is expected to serve as TIRC's exclusive ibogaine supplier for the United States, subject to the conclusion of a definitive agreement, which the parties have agreed to conclude on or before November 30, 2026.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NPX-5 | Adjustment disorder due to incurable cancer (Phase IIb, Australia, 87 patients) | small molecule | Phase 2 |
| Nature-derived psilocybin (PsyLabs API) | Alcohol use disorder and other substance use disorders | small molecule | Pre-clinical |
| Nature-derived ibogaine (right of first refusal) | Substance use disorders | small molecule | Pre-clinical |
Recent results and decisions
- Oct 21, 2026completed Psyence BioMed's PsyLabs completed an ibogaine regulatory readiness documentation package intended to support future regulatory interactions.
PsyLabs has completed its ibogaine regulatory readiness pack, a documentation package intended to support future regulatory interactions relating to pharmaceutical-grade ibogaine hydrochloride (HCl).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.